Evidence map›Paper›PMID 26635476›Full record

ArticleNeuropsychiatric disease and treatment2015

The ability of early changes in motivation to predict later antidepressant treatment response.

Philip Gorwood, Guillaume Vaiva, Emmanuelle Corruble, Pierre-Michel Llorca, Franck J Baylé, Philippe Courtet

Open access · goldAbstract read
In one paragraph

Article in Neuropsychiatric disease and treatment, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Observational
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

Philip GorwoodCentre Hospitalier Sainte-Anne (CMME), Paris, France ; Centre of Psychiatry and Neuroscience, INSERM U894, University Paris-Descartes, Paris, France.
Guillaume VaivaPôle de Psychiatrie, CHRU de Lille, Hôpital Michel-Fontan, Université Lille-Nord de France, Lille, France.
Emmanuelle CorrublePsychiatry Department of Bicêtre, University Hospital, INSERM U669, Paris XI University, Le Kremlin Bicêtre, France.
Pierre-Michel LlorcaCHU Clermont-Ferrand, Clermont Université, Université d'Auvergne, Clermont-Ferrand, France.
Franck J BayléCentre Hospitalier Sainte-Anne (CMME), Paris, France ; Centre of Psychiatry and Neuroscience, INSERM U894, University Paris-Descartes, Paris, France.
Philippe CourtetDepartment of Emergency Psychiatry, CHU Montpellier, Montpellier, France.
Assistance Publique – Hôpitaux de Paris · FRDélégation Paris 5 · FRInstitut de Psychiatrie et Neurosciences de Paris · FRNeuropsychiatrie : Recherche Epidemiologique et Clinique · FRSciences Cognitives et Sciences Affectives · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionBaseline values and early changes of emotional reactivity, cognitive speed, psychomotor function, motivation, and sensory perception have not been studied to any extent in unipolar depression, although they could help to characterize different dimensions of illness that are harder to capture by clinicians, give new insights on how patients improve, and offer new early clinical markers for later treatment response.

methodsAbout 1,565 adult outpatients with major depressive disorder receiving agomelatine completed the clinician-rated 16-item quick inventory of depressive symptoms, Clinical Global Impression, and Multidimensional Assessment of Thymic States (MAThyS) rating scales at inclusion, Week 2 and Week 6. The MAThyS includes a 20-item self-rated visual analog scale (from inhibition [0] to activation [10], with [5] representing the usual state) leading to five a priori dimensions (emotional reactivity, cognitive speed, psychomotor function, motivation, and sensory perception).

resultsAll MAThyS dimension scores increased from inclusion to Week 2 and from inclusion to Week 6 (P<0.001). Improvement was around 2 points (out of 10) for motivation, 1.5 points for psychomotor function, and 0.5 points for other dimensions. Motivation showed a trend to being more severely impaired at inclusion in future nonresponders (t=1.25, df=1,563, P=0.10). Its improvement at Week 2 was the most discriminating MAThyS dimension between future responders and nonresponders, and represents the best predictor of future response, with the highest area under the receptor operating characteristic curve (area under curve =0.616, 95% confidence interval [0.588-0.643], P<0.001). Finally, improvements in motivation correlated the most strongly with clinician-rated 16-item quick inventory of depressive symptoms improvement (r=-0.491, df=1,563, P<0.001).

conclusionMotivation had the most capacity for early improvement, the best predictive value for response, and the largest global margin of progress in depressed outpatients. Assessing the evolution of self-reported motivation over time in major depressive disorder could offer an interesting complementary approach to predict response.

Indexed as

agomelatinedepressiondimensionmotivationtreatment response

Identifiers

PMID26635476
PMCPMC4646593
OpenAlexW2175265594

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.